Cassava Sciences, Inc. (SAVA)

NASDAQ: SAVA · IEX Real-Time Price · USD
-1.25 (-2.90%)
At close: Sep 30, 2022 4:00 PM
+0.18 (0.43%)
After-hours: Sep 30, 2022 7:59 PM EDT
Market Cap 1.68B
Revenue (ttm) n/a
Net Income (ttm) -60.59M
Shares Out 40.10M
EPS (ttm) -1.16
PE Ratio n/a
Forward PE 39.84
Dividend n/a
Ex-Dividend Date n/a
Volume 2,039,321
Open 42.63
Previous Close 43.07
Day's Range 41.08 - 44.80
52-Week Range 13.84 - 100.00
Beta 0.52
Analysts Buy
Price Target 70.38 (+68.3%)
Earnings Date Nov 8, 2022

About SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, T... [Read more...]

Industry Pharmaceuticals
Founded 1998
CEO Remi Barbier
Employees 24
Stock Exchange NASDAQ
Ticker Symbol SAVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is 70.38, which is an increase of 68.29% from the latest price.

Price Target
(68.29% upside)
Analyst Consensus: Buy
Stock Forecasts


How High Can SAVA Stock Go Once the Controversy Clears?

Sometimes, it's hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ: SAVA ).

1 day ago - InvestorPlace

Should you buy Cassava Sciences as the stock continue to soar

Retail interest in Cassava Sciences (NASDAQ:SAVA) remains far from over. The stock gained more than 6.7% on Wednesday, catapulting it to a 76% increase in value in a month.

3 days ago - Invezz

Why Is Cassava Sciences (SAVA) Stock Heating Up Today?

Casava Sciences (NASDAQ: SAVA ) stock rose 5% overnight in sympathy with Biogen's (NASDAQ: BIIB ) successful clinical trial of an Alzheimer's drug called lecanemab. Lecanemab, developed with Eisai (OTCM...

3 days ago - InvestorPlace

5 Investors Betting Big on Cassava (SAVA) Stock

Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day's gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on...

1 week ago - InvestorPlace

The Huge Reason Cassava Sciences (SAVA) Stock Is Rocketing Higher

Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That's because the Securities and Exchange Commission (SEC) has closed its case ...

1 week ago - InvestorPlace

Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data

The SEC reportedly cleared an investigation into Cassava Sciences, leading SAVA stock to hit a seven-month high Thursday. The post Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Da...

1 week ago - Investors Business Daily

What Is Going on With Cassava (SAVA) Stock Today?

Cassava Sciences (NASDAQ: SAVA ) stock rose nearly 30% on Sept. 20 as speculators bet on the company's efforts against Alzheimer's Disease.

1 week ago - InvestorPlace

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited t...

3 weeks ago - GlobeNewsWire

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock

Cassava Sciences (NASDAQ: SAVA ) rose 9% overnight on reports director Richard Barry has invested $860,000 in the company's stock. The stock was due to open Aug. 26 at almost $30 per share, a market cap...

1 month ago - InvestorPlace

No Evidence of Data Manipulation in Science Publication on Simufilam

AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, was recently informed by the Journal of Pre...

1 month ago - GlobeNewsWire

Cassava Sciences, Blue Apron, and Revlon Stocks Exploded Out of the Gate Wednesday Morning

These vastly different companies have one thing in common.

Other symbols: APRNREV
1 month ago - The Motley Fool

Why Is Cassava Sciences (SAVA) Stock Up 20% Today?

Cassava Sciences (NASDAQ: SAVA ) rose 20% in overnight trading after board member Sanford Robertson bought 100,000 shares. Chief financial officer Eric Schoen also bought shares.

1 month ago - InvestorPlace

Stocks to watch: Apple, Digital World Acquistion Corp, Cassava Science, Canoo

Yahoo Finance Live host Seana Smith breaks down the action surrounding trending stocks in after-hours trading, including how the Trump-tied SPAC is filing to delay earnings.

Other symbols: GOEVAAPLDWAC
1 month ago - Yahoo Finance

Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of...

AUSTIN, Texas, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the s...

1 month ago - GlobeNewsWire

10 Stocks to Sell Before They Die

This article is excerpted from Tom Yeung's Profit & Protection newsletter dated July 28, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.

2 months ago - InvestorPlace

Cassava Sciences Responds to Media Reports

- In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures.

2 months ago - GlobeNewsWire

Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe

Cassava Biosciences (NASDAQ: SAVA ) stock is tumbling 30% in pre-market trading after Reuters reported today that the Justice Department has launched a criminal probe of the company. The news service ci...

2 months ago - InvestorPlace

US opens criminal probe into pharma company over potential Alzheimer's drug fraud: report

A Texas-based pharmaceutical company is facing a criminal probe into allegations that it manipulated data in its studies on its Alzheimer's drug simuflam on Wednesday.

2 months ago - Fox Business

Cassava's stock dives 24% after report citing alleged criminal probe of data from Alzheimer's drug trial

Shares of Cassava Sciences Inc. SAVA, +0.14% plunged 24.2% in premarket trading on Wednesday after Reuters reported that the Justice Department is investigating whether the company manipulated clinical ...

2 months ago - Market Watch

Exclusive-Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say

The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc involving whether the biotech company manipulated research results for its experimental Alzheimer's drug, two pe...

2 months ago - Reuters

7 Meme Stocks Trading at a Massive Discount Right Now

'Meme mania' has long since passed, but there may be an opportunity with these seven meme stocks trading at a discount right now. The post 7 Meme Stocks Trading at a Massive Discount Right Now appeared ...

2 months ago - InvestorPlace

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cassava Sciences, Inc.

Wilmington, Delaware--(Newsfile Corp. - July 7, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) on behalf of sto...

2 months ago - Newsfile Corp

5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

4 months ago - Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

NEW YORK , May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).  Such investors are advised to...

4 months ago - PRNewsWire

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

- $209.7 Million Cash and Cash Equivalents at March 31, 2022 –

4 months ago - GlobeNewsWire